Objective To evaluate the safety of cyclosporine(CsA)and methotrexate(MTX)in the treat-ment of psoriasis and to analyze the risk factors of side effects in the course of treatment. Methods In this retro-spective study,the patients with psoriasis treated with CsA and MTX were enrolled from April 2012 to April 2016 in Hainan Province. The clinical data and medication status of the patients were retrospectively collected. All pa-tients underwent laboratory tests such as blood,liver enzyme,renal function,and urine tests before treatment and during the follow-up. During the course of the study,any adverse events were recorded in the rotation treatment. Results A total of 42 psoriatic patients were enrolled. After screening,42 patients with psoriasis were enrolled. The average dosage and cumulative dose were(456.79 ± 472.14)days,and(134.68 ± 183.24)g for cyclosporine and(274.51 ± 215.32)days,(418.62 ± 435.63)mg for methotrexate.Four patients had abnormal laboratory tests after treatment:4 patients(9.5%)had abnormal transaminases and 2(4.8%)were accompanied by abnormal uric acid. The renal function tests(serum creatinine and blood urea nitrogen),blood cell count and urine tests for all patients were in the normal range. Conclusions In the long-term systemic treatment of chronic plaque psoriasis, the use of cyclosporine A and methotrexate therapy can largely reduce the side effects of drugs,especially the oc-currence of renal toxicity. In the course of treatment,the epidemiology of patient,duration of disease,severity of the disease,the dose and duration of drugs are not high risk factors for the side effects of drugs.

Electron Spin Resonance Spectroscopy ; Magnetic Resonance Spectroscopy ; Models, Molecular ; Protein Structure, Tertiary ; Proteins ; chemistry